-
Vivid brings over 30 years of operational and financial leadership in healthcare and life sciences, being a founder of LivaNova PLC, led OPEN Health as Interim Group CEO, and held senior roles at GlaxoSmithKline, Allergan, and LGC
-
Vivid will draw on his deep industry relationships and operational expertise to support GHO’s portfolio companies directly, while also helping to expand the firm’s network across the healthcare and life sciences sector
London, UK – GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, today announced that it has appointed Vivid Sehgal as Operating Partner.
Vivid joins with extensive experience in operational and financial leadership across multiple healthcare and life sciences businesses, having built substantial expertise throughout his career in cross-border mergers and acquisitions, business transformation, and international expansion across Europe, North America, and emerging markets.
He will work closely with GHO’s investment and operating teams to support portfolio companies as they scale, drawing on his extensive experience building and growing businesses across the healthcare and life sciences sector. Vivid’s appointment will also strengthen GHO’s network across the sector, providing portfolio companies with access to his connections across operators, advisors, and executives built over his career to date.
He most recently served as an Operating Advisor within the Goldman Sachs Value Accelerator and currently serves as Non-Executive Audit Chair and Advisor to Nexpring Health, a global MedTech company focused on Assisted Reproductive Technology. Additionally, he serves on the board of OPEN Health, a global healthcare marketing and communications company, where he previously served as Interim Group Chief Executive Officer from 2024 to 2025, and on the Shareholder Advisory Committee of Amedes Group, a leading provider of medical diagnostic and laboratory services in Europe. Prior to this, Vivid was Chief Financial Officer at LGC, a global life science tools company, from 2022 to 2024.
Earlier in his career, Vivid was a founding member of LivaNova PLC, a global medical technology company focused on neuromodulation and cardiac surgery solutions, which was created through the merger of Sorin and Cyberonics. The company subsequently listed on NASDAQ, with Vivid serving as Chief Financial Officer from 2015 to 2017. He has also held senior financial and commercial leadership positions at GlaxoSmithKline PLC, Gillette Company Inc. and Allergan Inc. during the company’s $66 billion sale.
Edward de Nor and Stuart Quin, Partners at GHO Capital, commented: “Vivid’s appointment marks an important step in strengthening our operating capabilities as GHO continues to scale. His proven track record of driving performance and value creation across complex, global healthcare and life sciences businesses, particularly in HealthTech and MedTech, will be a real asset to our portfolio companies as they pursue their next phase of growth. We’re delighted to welcome him to the team.”
Vivid’s appointment follows GHO’s 20 May 2026 announcement of its definitive agreement to combine with CBC Group. Once closed, the combination will create the world’s largest dedicated healthcare investment manager – spanning 13 offices across North America, Europe and Asia-Pacific, employing more than 200 investment and operating professionals, and managing $21 billion in AUM.
